A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Pattacini, Laura ^a   Mize, Gregory J ^a   Graham, Jessica B ^a   Fluharty, Tayler R ^a   Graham, Tisha M ^a   Lingnau, Karen ^b   Wizel, Benjamin ^b   Perdiguero, Beatriz ^c   Esteban, Mariano ^c   Pantaleo, Giuseppe ^d   Shen, Mingchao ^a   Spies, Gregory A ^a   McElrath, M Juliana ^a,e   Lund, Jennifer M ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b INTERCELL AG   (Austria)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CN54 GP140 HIV ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IC 31; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NEW YORK VACCINIA VIRUS CN54 PROTEIN; PLACEBO; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE COMPARISON; EFFECTOR CELL; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INTESTINE LYMPHATIC TISSUE; MEMORY T LYMPHOCYTE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; SPLEEN; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUM COMPOUNDS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DRUG COMBINATIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP120; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MESENTERY; MICE; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; VACCINIA VIRUS;

EID: 84864441978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042163     Document Type: Article

References (34)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. ((2008)) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:: 1881--1893.
2. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. ((2008)) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:: 1894--1905.
3. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. ((2012)) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122:: 359--367.
4. Perreau M, Pantaleo G, Kremer EJ, ((2008)) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205:: 2717--2725.
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. ((2009)) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:: 2209--2220.
6. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, et al. ((1992)) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:: 217--232.
7. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, ((2011)) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11:: 189--217.
8. Gomez CE, Najera JL, Jimenez EP, Jimenez V, Wagner R, et al. ((2007)) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:: 2863--2885.
9. Wild J, Bieler K, Kostler J, Frachette MJ, Jeffs S, et al. ((2009)) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22:: 309--319.
10. Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, et al. ((2009)) Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J Virol 83:: 5881--5889.
11. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, et al. ((2008)) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205:: 63--77.
12. Perreau M, Welles HC, Harari A, Hall O, Martin R, et al. ((2011)) DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol 85:: 9854--9862.
13. Zhu J, Martinez J, Huang X, Yang Y, ((2007)) Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:: 619--625.
14. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, et al. ((2009)) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5:: e1000480.
15. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. ((2006)) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:: 413--424.
16. Krieg AM, ((2007)) Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4:: 289--294.
17. Kwant A, Rosenthal KL, ((2004)) Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22:: 3098--3104.
18. Tritel M, Stoddard AM, Flynn BJ, Darrah PA, Wu CY, et al. ((2003)) Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171:: 2538--2547.
19. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, et al. ((2006)) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:: 1249--1258.
20. Fritz JH, Brunner S, Birnstiel ML, Buschle M, Gabain A, et al. ((2004)) The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22:: 3274--3284.
21. Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, et al. ((2006)) IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24:: 5461--5472.
22. Cui W, Kaech SM, ((2010)) Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 236:: 151--166.
23. Kaech SM, Hemby S, Kersh E, Ahmed R, ((2002)) Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:: 837--851.
24. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. ((2003)) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:: 225--234.
25. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K, ((2008)) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26:: 3461--3468.
26. Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, et al. ((2011)) The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 29:: 4256--4263.
27. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. ((2012)) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:: 1275--1286.
28. Stoecklinger A, Eticha TD, Mesdaghi M, Kissenpfennig A, Malissen B, et al. ((2011)) Langerin+ dermal dendritic cells are critical for CD8+ T cell activation and IgH gamma-1 class switching in response to gene gun vaccines. J Immunol 186:: 1377--1383.
29. West EE, Youngblood B, Tan WG, Jin HT, Araki K, et al. ((2011)) Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity 35:: 285--298.
30. Cheng C, Cruz-Fisher MI, Tifrea D, Pal S, Wizel B, et al. ((2011)) Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31(R). Vaccine 29:: 2437--2443.
31. Rehli M, ((2002)) Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23:: 375--378.
32. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, et al. ((2011)) Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29:: 2100--2109.
33. Lindblad EB, ((2004)) Aluminium compounds for use in vaccines. Immunol Cell Biol 82:: 497--505.
34. Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, et al. ((2011)) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A 108:: 7131--7136.